title: [Comparative evaluation of clinical use of cardioplegic solutions custodiol and konsol in the correction of cardiac valvular diseases].
abstract: The efficiency of myocardial protection with cold crystalloid cardioplegia (CC) during operations on the heart under total ischemia and extracorporeal circulation was studied. Two hundred and fifty patients who underwent prosthetic or plastic repair of the aortic and mitral valves or plastic repair of the tricuspid valve were examined. Group 1 comprised 218 patients in whom the myocardium was protected with Konsol solution ("Biofarm "research-and-production enterprise, Russia); Group 2 included 32 patients in whom Custodiol solution ("Dr Franz Kohler Chemia GMBH", Germany). The volume of the Konsol solution required for CC was 400-2000 ml, with the duration of myocardial ischemia (MI) being 75 +/- 33 min; that of the Custodiol was 2000-4000 ml, with the duration of MI being 80 +/- 22 min. The used algorithm of administration of the solutions provided a persistent cardioplegic effect in both groups. After aortic declamping, there was a spontaneous recovery of cardiac performance in 84 and 40% in Groups 1 and 2, respectively. In the reperfusion period (RP), no significant differences were found in the basic hemodynamic parameters (heart rate, blood pressure, and central venous pressure) in both groups. After defect correction, cardiac output equally increased in both groups. The groups did not differ in the rate of inotropic support either. In RP, transient cardiac rhythm and conduction disturbances occurred in 19 and 28% in Groups 1 and 2, respectively.
authors.forename: I L
authors.initials: IL
authors.lastname: Zhidkov
authors.forename: V A
authors.initials: VA
authors.lastname: Kozhevnikov
authors.forename: V A
authors.initials: VA
authors.lastname: Ivanov
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Morozov
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Andrianova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Van
authors.forename: N A
authors.initials: NA
authors.lastname: Trekova
mesh_terms: D002314:Cardioplegic Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000601:surgery*; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism; D011189:Potassium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D011343:Procaine / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C039984:Bretschneider cardioplegic solution; D002314:Cardioplegic Solutions; D008353:Mannitol; D011343:Procaine; D011189:Potassium Chloride; D005947:Glucose